Eye Melanoma Global Market Demand Analysis, Manufacturers Share, Regions, Risk Analysis, Driving Forces and Application, Forecast To 2033 | AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca PLC, Sanofi S.A.

The eye melanoma market size has grown strongly in recent years. It will grow from $8.29 billion in 2023 to $9.1 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increased awareness and early detection, aging population and sun exposure, rise in skin cancer incidence, development of targeted therapies, patient advocacy and support programs..

The eye melanoma market size is expected to see strong growth in the next few years. It will grow to $12.61 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to continued public health initiatives, research in genetic and molecular profiling, global aging population trends.. Major trends in the forecast period include integration of artificial intelligence (ai), emergence of targeted therapies, focus on rare disease drug development, patient-centric drug approval processes, advancements in diagnostic imaging, advancements in treatment modalities, technological innovations in imaging..

Market Overview -
Eye melanoma is a type of cancer that develops in the melanocytes, the cells that produce melanin within the eye. It occurs in different parts of the eye, including the uvea, the iris, and the choroid. Eye melanoma is the most common primary intraocular cancer in adults and can cause vision problems, changes in eye color, and other symptoms depending on its location and size.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13109&type=smp

Rising Prevalence Of Eye Cancer Boosts Growth Prospects For The Eye Melanoma Market
The increasing prevalence of eye cancer is expected to propel the growth of the eye melanoma market going forward. Eye cancer refers to the development of abnormal and uncontrolled cell growth within the eye's structures. The growing recognition and effective management of early cases are creating a heightened need for specialized therapies and interventions, propelled by improved detection methods, increased awareness, and advancements in treatment options. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of eye and orbital cancer cases increased to 3,490 in 2023, reflecting a growth of 5.12% from 3,320 in 2021. Therefore, the increasing prevalence of eye cancer will drive the growth of the eye melanoma market.

Competitive Landscape -
Major companies operating in the eye melanoma market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Koninklijke Philips N.V., Carl Zeiss AG, Genentech Inc., Elekta Instrument AB, Brainlab AG, Optos Plc , Castle Biosciences Inc., Heidelberg Engineering, Nektar Therapeutics, RaySearch Laboratories AB, Nidek Co. Ltd, IDEAYA Biosciences, Immunocore Limited , Topcon Healthcare, Oraya Therapeutics Inc., Delcath Systems Inc.

Pioneering Advances In Eye Melanoma Treatment For Unresectable Or Metastatic Uveal Melanoma
Major companies operating in the eye melanoma treatment sector are focused on developing innovative and specialized treatments, such as immunotherapies and targeted therapies, to enhance patient outcomes and quality of life. Immunotherapies and targeted therapies are novel treatment modalities that have recently begun to enter the oncology field. For instance, in January 2022, Immunocore Ltd., a UK-based biopharmaceutical company that focuses on research and development of biological drugs using soluble T-cell receptor technology, received approval from the U.S. Food and Drug Administration (FDA) for Kimmtrak (tebentafusp-tabn), a T-cell receptor therapeutic, which is the first therapy for individuals with unresectable or metastatic uveal melanoma (mUM). Kimmtrak is an immunotherapy that targets a specific protein called gp100, which is present on the surface of uveal melanoma (UM) cells. It activates the patient's immune system to eliminate melanoma by engaging specialized immune cells through engineered T-cell receptors, offering a precision-driven approach to cancer treatment.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Key Segments -
The eye melanoma market covered in this report is segmented -
1) By Site: Uvea, Sclera, Retina
2) By Diagnosis: Imaging, Biopsy, Eye Exam
3) By Treatment: Surgery, Radiation Therapy, Targeted Therapy, Immunotherapy, Other Treatment
4) By End User: Hospitals And Clinics, Academic Institutes

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.